Wheeler Andrew A, Nicholl Michael B
Department of Surgery, University of Missouri, Columbia, MO, USA.
Division of Surgical Oncology, University of Missouri, Columbia, MO, USA.
World J Oncol. 2014 Feb;5(1):7-13. doi: 10.14740/wjon789w. Epub 2014 Mar 11.
Pancreatic cancer (PanCA) is predominantly diagnosed in elderly patients; nevertheless, a significant number of young patients are affected. We hypothesized more aggressive treatment of young PanCA patients would result in better overall survival (OS).
A retrospective review of our institutional cancer database identified subjects for inclusion. Age 50 years was selected to stratify patients into age groups.
Of 309 PanCA patients, 54 (17%) were ≤ 50 years old. Exocrine cancer was the most common histology (90%). Patients ≤ 50 years old were more likely to have endocrine cancer (22% vs. 7%, P = 0.001). There was no difference in stage or curative intent surgery between age groups. Despite patients ≤ 50 years old receiving more chemotherapy (61% vs. 41%, P = 0.007) and radiotherapy (28% vs. 15%, P = 0.03), there was no difference in OS (24.1 months vs. 14.1 months, P = 0.08). When only exocrine cancers were considered, there was no difference between young and old patients regarding stage, grade, location or surgery. Exocrine cancer patients ≤ 50 years old received more chemotherapy (67% vs. 42%, P = 0.003) and radiation therapy (36% vs. 17%, P = 0.004), but there was no difference in OS.
A substantial number of PanCA patients are ≤ 50 years old. Patients ≤ 50 years old received more treatment but did not have improved OS. Significant improvements in PanCA survival await development of new treatment strategies.
胰腺癌(PanCA)主要在老年患者中被诊断出来;然而,也有相当数量的年轻患者受到影响。我们假设对年轻的胰腺癌患者进行更积极的治疗会带来更好的总生存期(OS)。
对我们机构的癌症数据库进行回顾性分析,以确定纳入的受试者。选择50岁作为年龄分组的界限。
在309例胰腺癌患者中,54例(17%)年龄≤50岁。外分泌癌是最常见的组织学类型(90%)。年龄≤50岁的患者更易患内分泌癌(22%对7%,P = 0.001)。年龄组之间在分期或根治性手术意图方面没有差异。尽管年龄≤50岁的患者接受了更多的化疗(61%对41%,P = 0.007)和放疗(28%对15%,P = 0.03),但总生存期并无差异(24.1个月对14.1个月,P = 0.08)。仅考虑外分泌癌时,年轻和老年患者在分期、分级、位置或手术方面没有差异。年龄≤50岁的外分泌癌患者接受了更多的化疗(67%对42%,P = 0.003)和放疗(36%对17%,P = 0.004),但总生存期没有差异。
相当数量的胰腺癌患者年龄≤50岁。年龄≤50岁的患者接受了更多治疗,但总生存期并未改善。胰腺癌生存的显著改善有待新治疗策略的开发。